mTOR inhibitors in renal cell carcinoma
- 1 July 2011
- journal article
- Published by OMICS Publishing Group in Therapy
- Vol. 8 (4), 359-367
- https://doi.org/10.2217/thy.11.32
Abstract
The mammalian target of rapamycin (mTOR) is a downstream effector of the PI3-K/Akt/mTOR pathway. Allosteric inhibitors of mTOR, everolimus and temsirolimus, have shown promising clinical activity in advanced renal cell carcinoma but their effect is far from durable and only a subset of patients experience substantial benefit from these agents. The PI3-K/Akt/mTOR pathway represents an intricate network of fine regulation and feedback loops, and resistance to allosteric mTOR inhibitors may be embedded within this complexity. In this article we highlight the molecular elements of the PI3-K/Akt/mTOR pathway, the clinical experience with everolimus and temsirolimus in advanced renal cell carcinoma, and the future directions in terms of sequential therapy, combinational therapy and development of novel therapeutic agents.Keywords
This publication has 34 references indexed in Scilit:
- Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccinesBritish Journal of Cancer, 2011
- Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitroCancer Immunology, Immunotherapy, 2010
- mTOR regulates memory CD8 T-cell differentiationNature, 2009
- FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivoBritish Journal of Cancer, 2009
- Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2Online Journal of Public Health Informatics, 2008
- HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal CarcinomaCancer Cell, 2008
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translationProceedings of the National Academy of Sciences of the United States of America, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancerNature Medicine, 2005
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005